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We review here evidence defining a molecular pathway that includes cell cycle-related molecules and that appears to play a required role in
neuron death during normal development as well as in disease and trauma. The pathway starts with inappropriate activation of cyclin dependent
kinase 4 (Cdk4) in neurons which leads to hyper-phosphorylation of the pRb family member p130. This in turn results in dissociation of p130 and
its associated chromatin modifiers Suv39H1 and HDAC1 from the transcription factor E2F4. Dissociation of this complex results in de-repression
of genes with E2F binding sites including those encoding the transcription factors B- and C-Myb. Once elevated in neurons, B- and C-Myb
proteins bind to the promoter for the pro-apoptotic BH3-only protein Bim and promote its induction. Bim then interacts with the core cellular
apoptotic machinery, leading to caspase activation and apoptotic death. This pathway is supported by a variety of observations and experimental
findings that implicate it as a required element for neuron loss in development and in many nervous system traumas and disorders. The
components of this pathway appear to represent potential therapeutic targets for prevention of disease-associated neuron death.
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As recounted by reviews in this special issue and elsewhere
[1–12], cell cycle-related molecules appear to play key roles in
neuron death associated with development and disease. Our aim
here will be to describe the components of a molecular pathway
in which cell cycle elements participate in neuron death. We
will relate how activation of a cyclin-dependent kinase in
neurons triggers a chain of molecular events that ultimately
engages the core apoptotic machinery and culminates in cellular
demise.
There are six overarching themes of this article. The first is
that there are striking and mutually informative similarities
between the molecular mechanisms that govern neuron death
during normal development and in neurological disorders. The
second is that neuron death in both instances involves similar⁎ Corresponding author. Fax: +1 212 305 5498.
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doi:10.1016/j.bbadis.2006.12.003changes in the activities and expression of molecules otherwise
associated with the cell cycle. The third is that the pathway
includes the sequential activation of cyclin-dependent kinase 4
(Cdk4); hyper-phosphorylation of the Rb family member p130;
dissociation of p130 and associated chromatin modifiers from
the transcription factor E2F4, resulting in gene de-repression;
de-repression of the genes encoding the transcription factors B-
and C-Myb; enhanced occupancy by B- and C-Myb of the
promoter for the pro-apoptotic BH3-only protein Bim; and
activation by Bim of the core apoptotic machinery. The fourth
theme is that neuron death mediated by this pathway is not
simply due to an aborted attempt to traverse the cell cycle, but
rather reflects alternative actions of molecules that are also
involved in cell proliferation. Fifth, although this pathway is
necessary for neuron death under many conditions, it is not
sufficient and works in conjunction with additional signaling
pathways to mediate apoptosis. Lastly, our understanding of the
specific molecules that contribute to neuron death in disease
provides targets for novel therapeutic opportunities.
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During normal vertebrate development, approximately 50%
of all post-mitotic neurons that are born undergo cell death [13].
An abundance of evidence supports a model in which the
decision of which neurons live or die is regulated by their
competition for limiting amounts of target-derived trophic
factors [14–17]. The best studied of these trophic factors with
respect to neuronal survival and death is nerve growth factor
(NGF). In vitro studies, largely (but by no means exclusively)
carried out with rodent sympathetic neurons and PC12
pheochromocytoma cells have revealed a wealth of information
about what happens in nerve cells when they are deprived of
NGF and how this results in their apoptotic death. This has been
strongly complemented by in vivo and in vitro studies with
other trophic factor systems and models.
Among early observations relevant to our theme was that
NGF deprivation in sympathetic neuron cultures was followed
by elevation of transcripts encoding cyclin D1 (CycD1), a
regulator of cyclin dependent kinases 4 and 6 (Cdk4/6) [18]. In
proliferation-competent cells, an increase in CycD1 protein
levels triggers movement from the G0 or G1 phase of the cycle
into G1/S [19,20]. It was also reported that the apoptotic
stimulus of serum deprivation in cultures of neuronally
differentiated murine neuroblastoma cells resulted in activation
of CycD1-dependent cdk activity [21]. Moreover, blockade of
this activity by over-expression of the cdk inhibitory protein
p16INK4A1, was protective. Additional evidence linking loss
of trophic support to dysregulation of G1/S markers and other
cell cycle proteins came from a genetic model in which post-
mitotic cerebellar granule cells die due to loss of their synaptic
targets and presumptive source of trophic support [22]. In this
model, neuron death was also associated with elevation of
cyclin D and other cell cycle-related proteins.
If G1/S-related events are required for developmental neuron
death, it follows that agents that interfere with the G1/S
transition should be protective. Indeed, blockade of this
transition with a dominant-negative form of Ras or with a
variety of small chemical G1/S inhibitors effectively rescued
neuronal cells from NGF deprivation [23,24].
The potential involvement of cyclin D1 in developmental
neuron death implicates its partners cdks 4 and 6. These play
important roles in permitting replication-competent cells to
undergo the G1/S transition [19,20]. One test of the potential
importance of these proteins in developmental cell death has
been the employment of small chemical cdk inhibitors such as
olomoucine, roscovitine and flavopiridol. These have proved to
be remarkably effective in blocking neuronal apoptosis evoked
by trophic factor deprivation [25–29]. Although widely
employed, one weakness of such drugs is that they lack
specificity both within the cdk family and with respect to other
kinases [30–33] and this has complicated the mechanistic
interpretation of their actions in neuron death. An alternative
approach has been the delivery of constructs encoding
naturally occurring cdk inhibitor proteins such as p21, p16
(INK4A1), and p27(kip1). Over-expression of these proteins
protects neurons from trophic factor deprivation, reinforcing arole for cdks in neuronal developmental cell death [21,34]. To
test the roles of specific cdks in neuron death, dominant-
negative forms of these proteins have been expressed in
neurons. It was observed that virally-delivered dominant-
negative forms of Cdk4 and 6, but not of Cdk2 and Cdk3
protected sympathetic neurons from NGF deprivation [34].
Because of the potential capacity of dominant negative
constructs to interact with and inhibit shared targets and
regulators, we have more recently used shRNAs to specifically
knock down Cdk4 [35]. This too has protected against NGF
deprivation, further implicating this partner of CycD1 as a
required element in the mechanism by which loss of trophic
support triggers apoptotic death.
Although Cdk4 has multiple potential targets, its major
substrates during cell proliferation are members of the Rb
family of “pocket” proteins, namely pRb, p107 and p130
[19,20]. (In this review, we will use Rb to refer to the entire
family and pRb to indicate this specific family member). In
proliferating cells, hyper-phosphorylation of Rb by Cdk4 is an
important event in the G1/S transition. In accordance with the
involvement of Cdk4 activation in developmental neuron death,
all three Rb family members rapidly undergo hyper-phosphor-
ylation in response to trophic factor deprivation [28,36].
Although initial studies focused on pRb and its role in
survival and death of post-mitotic neurons [37,38], more recent
findings suggest that this protein may be more involved in
regulating proliferation of neuronal precursor cells than in
maintaining neuron survival [39,40]. Our findings suggest that
the family member that is most important for regulating neuron
survival and death in p130 [36]. In support of this,
electrophoretic mobility shift assays (EMSA) indicate that
relevant E2F-binding DNA complexes formed in post-mitotic
neurons contain mainly p130 rather than pRb or p107.
Moreover, the importance of p130 in neuron survival is
underscored by the observation that knockdown of p130, but
not of pRb or p107 induces neuron death [36].
How does p130 maintain neuron survival and how does its
hyper-phosphorylation by Cdk4 result in developmental neuron
death? An important (but not the only) activity of Rb family
proteins is to associate with members of the E2F transcription
factor family [19,20]. Such complexes have two roles. One is to
suppress E2F's transactivating activity and the other is to
repress genes to which they are bound. Hyper-phosphorylation
of Rb by Cdk4 causes such complexes to dissociate. This has
two potential consequences: release of E2F so that it can now
transactivate suitable targets and de-repression and induction of
genes otherwise silenced by E2F–Rb complexes [19,20].
In response to trophic factor deprivation, as described above,
p130 undergoes hyper-phosphorylation. It appears that a major
effect of this is translocation of p130 out of the nucleus [36].
This presumably further reduces its capacity to participate in
gene repression. EMSA, chromatin immunoprecipitation
(ChIP) and luciferase reporter assays all confirm that the
associations of p130 with its DNA targets are lost in response to
NGF deprivation and that this requires cdk activity [36].
As noted above, loss of p130–E2F complexes due to hyper-
phosphorylation by activated Cdk4 permits both elevated E2F
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binding sites. Of these, multiple lines of evidence point to the
latter as the most relevant to developmental neuronal death
[41]. For instance, a decoy DNA construct with multiple E2F
binding sites that effectively soaks up endogenous E2F is
sufficient to trigger neuron death. This is consistent with the
de-repression mechanism of death in that sequestration of E2F
should result in loss of E2F–p130 complexes from DNA. On
the other hand, if death were due to E2F-driven transactiva-
tion, such a construct would be (but is not) protective. Another
supportive finding is that constructs encoding phosphoryla-
tion-resistant Rb mutants or fusion proteins between E2F and
Rb, which should selectively bind to and silence genes with
E2F binding sites, effectively protect neurons from NGF
deprivation [36,41]. As discussed below, additional experi-
ments show de-repression of specific death-associated genes
when NGF is withdrawn.
There is partial insight as to how p130 represses genes that
lead to developmental neuron death. In addition to associating
with E2F, Rb family members simultaneously bind molecules
that remodel chromatin [36]. Thus, within complexes with E2F,
Rb family members serve as tethers for proteins that modify
chromatin and that promote gene silencing. Two such p130-
associated proteins have been identified in neurons, histone
deacetylase (HDAC1) and Suv39H1 [36]. Both are associated
with p130 in healthy neurons and both are lost from complexes
with p130 and E2F on DNA under conditions of NGF
withdrawal [36]. Suv39H1 (suppressor of variegation 3–9
homolog 1) is a histone methyltransferase that transfers methyl
groups to lysine 9 on histone H3 [42] while HDAC1
deacetylates histones [43]. Both modifications promote gene
repression. As evidence of its role in maintaining neuron
survival, loss of cellular Suv39H1 or transfection with an
Suv39H1 mutant that binds p130 but lacks methyltransferase
activity causes both gene de-repression and neuron death [36].
In addition, inhibition of HDAC activity also leads to gene de-
repression and to neuron death [36,44,45]. Finally, although
E2F–p130 fusion constructs protect neurons from NGF
deprivation, such constructs that are defective in binding
HDAC and Suv39H1 lack protective activity [36]. There are
other chromatin modifiers in addition to HDAC1 and Suv39H1
that could conceivably play roles in p130-dependent neuron
survival (cf. [46]) and it will be of interest to identify these in
future studies.
Like the Rb family, the E2F family consists of multiple
members and there appears to be a selectivity for the association
between specific Rb and E2F proteins [19,20,47,48]. In
particular, the preferred partners for p130 are E2F4 and E2F5.
Our finding indicate the most relevant partner for p130 in
maintaining neuron survival is E2F4 [36]. E2F4, but not other
E2F family members were found to occupy the promoter of the
E2F-repressed pro-apoptotic gene B-Myb in healthy neurons
(see below for further discussion) and was bound there to p130,
but not pRb or p107. In addition, knock-down of E2F4, as in the
case of p130, is sufficient to trigger apoptotic neuronal death.
Taken together, such findings support the view that intact
E2F4–p130 complexes and their associated chromatin modi-fiers are required to maintain neuron survival and that in trophic
factor deprivation, such complexes are lost, resulting in de-
repression of genes that promote death.
A key issue regards the identities of the death-associated
genes that are repressed by p130–E2F4 complexes to maintain
neuron survival. One important family of such molecules has
been identified to date, the B- and C-members of the Myb
family of transcription factors. B- and C-Myb are classic
examples of genes that possess binding sites for E2F and that
are repressed by E2F–Rb family member complexes [49,50].
In response to cdk-dependent hyper-phosphorylation of Rb
family members in proliferating cells, B- and C-Myb are
induced and play major roles in promoting cell cycle
progression [49,50]. B- and C-Myb are also induced in neurons
after NGF deprivation [41], but in this case, they promote
apoptotic death. In healthy neurons, the promoters for B- and
C-myb are occupied by p130–E2F4 along with Suv39H1 and
HDAC1, and B- and C-Myb expression is suppressed. In
response to NGF deprivation, E2F4–p130-Suv39H1/HDAC1
complexes are lost from at least the B-myb promoter and
expression of Myb transcripts and protein is elevated [36]. This
induction promotes death in that over-expression of B- or C-
myb triggers neuronal apoptosis while suppression of B- or C-
myb induction by siRNA or antisense constructs protects
neurons from NGF deprivation [41,51]. These findings thus
establish that B- and C-Myb are among the genes that are de-
repressed in neurons when p130 is hyper-phosphorylated after
NGF deprivation and that their expression is required for
apoptotic death under such conditions.
Because Mybs are transcription factors, their role in neuron
death most likely results from regulation of other genes. To
date, we have identified one important and relevant target of
Mybs in cells deprived of trophic support and this is the
apoptosis facilitator molecule Bim/Bcl2-like 11. Bim is a pro-
apoptotic member of the Bcl2 family that belongs to the
subgroup of BH3-only proteins [52,53]. Current evidence
indicates that Bim binds to and neutralizes the function of pro-
survival proteins such as Bclx and Bcl2 and by this means
promotes caspase activation and apoptotic death. Bim is
induced in response to NGF deprivation and its knockdown
partially protects neurons from withdrawal of trophic support
[35,54–56]. Therefore, it appears to be among the regulated
genes that are involved in promoting developmental neuron
death. Two binding sites for Mybs have been found in the Bim
promoter. Significantly, we found that mutation of these sites
abolishes the induction of a Bim reporter construct that occurs
in response to NGF deprivation [35]. Moreover, occupancy of
these sites by at least C-myb is elevated by NGF withdrawal.
Additional evidence that Bim is a target of Mybs comes from
findings that induction of Bim by NGF deprivation is blocked
by Myb shRNAs [35]. In line with the pathway described
above, Bim induction via Mybs during NGF deprivation is
dependent on Cdk4 and E2F-mediated gene de-repression
[35]. Thus, Bim induction after NGF withdrawal is blocked by
cdk inhibitors and Cdk4 shRNA and is suppressed by the
E2F–Rb fusion construct described above that silences genes
with E2F binding sites.
Fig. 1. Scheme depicting a molecular pathway by which cell-cycle-related molecules promote cell death in neurons in development and disease. (A) Survival
conditions. Under conditions of neuron survival, p130 forms complexes with E2F4 on the promoters of genes including those encoding B- and C-Myb. p130 tethers
chromatin-modifying proteins such as Suv39H1 and HDAC1 to the promoter and represses their transcription. Cdk4 is inactive and consequently p130 is hypo-
phosphorylated and binds tightly to E2F4. (B) Apoptotic conditions. Under apoptotic conditions, Cdk4 associates with Cyclin D and is active. This leads to hyper-
phosphorylation of p130 which in turn causes it and its bound chromatin modifiers to dissociate from E2F4 and from promoters of genes including B- and C-Myb. This
results in gene de-repression and elevation of cellular levels of B- and C-Myb. TheMybs bind to the promoter of the gene encoding the pro-apoptotic BH3-only protein
Bim. The levels of intracellular Bim rise and it engages the core cell death machinery, promoting caspase activation and apoptosis.
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cycle-related events that are triggered by loss of trophic support
in neurons constitute a pathway that culminates in induction
of at least one protein, Bim, with clear pro-apoptotic activity
and in apoptotic death (see the scheme in Fig. 1). To sum-
marize, loss of trophic support in models of developmental
neuron death leads sequentially to (1) activation of Cdk4; (2)
hyper-phosphorylation of p130; (3) dissociation of complexes
containing E2F4, p130, Suv39H1 and HDAC1; (4) de-
repression of genes occupied by the latter complexes, including
those encoding B- and C-myb; (5) accumulation of elevated
levels of cellular B- and C-myb proteins; (6) binding of B- and
C-myb to the promoter for the gene encoding the pro-apoptotic
protein Bim; (7) induction of Bim protein; (8) engagement and
activation of the core apoptotic machinery by Bim via its neu-
tralization of pro-survival Bcl2 proteins; (9) caspase activation
and death.
3. Cell cycle molecules in neuron death associated with
diverse apoptotic stimuli
Although many of the mechanistic studies described above
have focused on neuron death associated with NGF deprivation,
it is important to emphasize that at least several aspects of this
scheme appear to pertain to a number of additional apoptotic
paradigms. For instance, many of the cell cycle pathway
elements that characterize neuron death evoked by NGF
deprivation also mediate death of both peripheral and CNS
neurons caused by DNA damaging agents [51,57,58]. Compo-
nents of this pathway have also been implicated death of variousneuron types brought about by various insults including
hypoxia [59,60], excitotoxic injury [61–63], physical trauma
[64], proteasomal inhibitors [65–67], and withdrawal of support
by hyperpolarizing levels of K+ [28]. Such considerations by no
means imply that the pathway described here or variations that
employ alternative sets of cycle-related proteins are universally
involved in neuron death. Nevertheless, present data encourage
us to consider the apoptotic cell-cycle pathway in paradigms
well beyond just the case of NGF deprivation. In this context,
we next review evidence for the role of the apoptotic cell cycle
pathway in neurological disorders.
4. Cell cycle molecules in neuron death associated with
neurological disorders: parallels with developmental
neuron death
Several types of evidence have linked cell cycle molecules to
neuron death in disease. The first are correlative observations
that cell cycle-related proteins are elevated in neurons that are at
risk to die in various neurodegenerative disorders, traumatic
injuries and ischemia/stroke, either in human disease or models
thereof. These findings have been extensively reviewed in this
volume and elsewhere and so need not be recounted here in
depth. However, of particular relevance is that these changes
include the same molecules involved in developmental neuron
death. For instance neuronal cyclin D is elevated in models of
ischemia/stroke [58,59,68–73], ALS [74], Alzheimer disease
(AD) [75], excitotoxic stress [67–69], and spinal cord injury
[64] as well as in affected neurons in human patients with AD
[76–79], ischemia [80] and sporadic ALS [81]. Likewise,
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ischemia/stroke [58,73], excitotoxicity [62], and ALS [74] as
well as in neurons from patients with AD [76,82] and stroke
[80]. Consistent with elevated cyclin D and Cdk4, phospho-pRb
immunostaining in relevant neurons is increased in models of
ischemia/stroke [59,83,84] and AD [85,86] and in patients with
Parkinson's Disease (PD) [87], AD [79,88] and sporadic ALS
[81]. With respect to Bim induction, this has been found for
experimental optic nerve transection [89], seizure [90] and
neonatal hypoxia/ischemia [91] and in human seizure [90].
Western immunoblotting of AD and control frontal cortex also
revealed elevation of Bim protein in the former [92].
Although there has been little work on Mybs in neurode-
generative diseases, there is evidence for their de-repression in
at least one human disorder, autoimmune paraneoplastic
cerebellar degeneration (PCD). In this malady, the target
antigen of auto-antibodies is pcd-17, a protein that blocks B-
myb de-repression [93]. The pcd-17 auto-antibodies appear to
enter Purkinje cells and block pcd-17 function and by this
means, permit B-Myb de-repression and consequent death.
The second type of evidence that cell-cycle related molecules
play roles in nervous system disease is based on experimental
manipulation of their activity or expression in cell culture and
animal models. Among the most widely used approaches is the
application of small chemical Cdk inhibitors (generally
olomoucine, roscovitine or flavopiridol, though others have
also been employed) to disease models and the demonstration
that these have ameliorative actions on behavior and/or neuron
survival. Examples in which this approach has been successful
include models of AD [64], ischemia/stroke [58,94], excitotoxic
stress [63,95,96], Niemann–Pick Disease [97], traumatic brain
injury [98], optic nerve transection [99], and spinal cord injury
[100].
While the experimental use of such chemical inhibitors has
supported the involvement of a cdk-dependent pathway in
disease-related neuron death and may well point the way to
clinically useful drugs, there are several serious reservations
about this interpretation. One issue regards the specificity of
such agents for cdks. As in the case of most drugs, one cannot
rule out actions on other classes of enzymes, especially kinases,
and indeed such activities have been described for flavopiridol,
olomoucine and roscovitine (cf [30–33]). However, the fact
that all three inhibitors seem to have similar actions in
protecting neurons does argue that non-cdk actions are less
likely.
A related concern is the selectivity of these agents for various
cdk family members. Each of these drugs targets different cdks
with variable levels of specificity. For instance, flavopiridol has
been described as a “pan-cdk” inhibitor [32] and there are no
published reports in which the actions of flavopiridol or other
such inhibitors have been systematically evaluated on all known
cdks. To compound the issue, accumulating evidence has
implicated Cdk5, which is a target of many cdk inhibitors, in
neuron death associated with neurological disorders [101–105].
This raises several possibilities. One is that cdks other than, or
in addition to, Cdk4 are involved in disease-related neuron
death. In this light, Rashidian et al. [84] have suggested thatboth Cdk4 and Cdk5 play complementary roles in neuron death
in hypoxia/ischemia with Cdk4 regulating apoptotic-like death
and Cdk5 promoting excitotoxic death. Another possibility is
that cdks in addition to Cdk4 drive hyper-phosphorylation of Rb
family members. It has been recently reported that activated
Cdk5 can directly hyper-phosphorylate Rb in a neuronal cell
death model [106]. If this finding holds for additional death
paradigms, it may be that disease-related Cdk5-dependent
neuron death is, at least in part, mediated via the phospho-p130/
Myb/Bim pathway described here.
Owing to the potential limitations of present small chemical
cdk inhibitors, alternative strategies are required to test the
involvement of specific cdks in disease-associated neuron
death. One approach has been the use of dominant-negative
cdks. Studies with such reagents showed that dominant-
negative forms of Cdk4 and 6 protected cultured neurons
from death evoked by β-amyloid [86]. Because dominant-
negative proteins may have non-selective actions such as
interactions with substrates common for other cdks, we have
employed a knockdown strategy with shRNAs. We find that an
shRNA targeted to Cdk4 protects cultured neurons from β-
amyloid [107], thus reinforcing the conclusion that at least in
this model, Cdk4 is required for neuron death. This observation
also supports the idea that Cdk4 mediates neuron death in
neurodegenerative disorders such as AD in which it appears to
be elevated and/or activated.
Our finding that knockdown of Cdk4 suppresses death
evoked by β-amyloid has led us to further pursue the hypothesis
that the same pathway identified in developmental cell death is
also activated in AD. We found that neuron death in the cellular
β-amyloid model was associated with induction of Bim
message and protein and that shRNA targeted to Bim was
highly protective [107]. Moreover, Bim induction as well as
death were blocked in this system by knocking down B-Myb.
Thus, in this cellular AD model, many of the same cycle-related
mechanisms that characterize the death induced by NGF
deprivation are present, including the requirement for Cdk4,
hyper-phosphorylation of Rb proteins and the essential induc-
tion of B-Myb and Bim.
Indications that the above pathway mediates neuron death by
β-amyloid in culture have led us to explore whether this might
also occur in AD itself. As reviewed above, susceptible neurons
in AD show elevated expression of cyclin D, Cdk4 and hyper-
phosphorylated Rb. We find that a large proportion of such
neurons also co-express elevated levels of Bim [107]. These
findings thus establish that affected neurons in AD brains
express both the distal and proximal elements of the death
pathway we have defined in developmental neuron death and in
cellular models of AD. We would anticipate comparable
findings in additional neurological disorders.
5. Other cell cycle elements in neurological disease
The molecules that constitute the pathway described here
(cyclin D, Cdk4, phospho-Rb and Mybs) are normally
associated with the G1/S transition. However, a potential
complication is the somewhat bewildering observation that
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elevation of proteins that are considered to be markers of
additional phases of the cycle in proliferating cells. How do
these additional cell cycle proteins fit into the scheme presented
here? A variety of approaches have revealed that E2F–Rb
complexes, including E2F4–p130, bind to and regulate
numerous cell-cycle associated genes [48,108]. In proliferating
cells, hyper-phosphorylation of Rb and loss of such complexes
permits induction of genes that promote DNA synthesis and an
orderly progression to the next stages of the cycle. In neurons,
by contrast, hyper-phosphorylation and loss of E2F–Rb
complexes will also lead to induction of multiple cell-cycle
associated proteins, but in this case, leads to cell death.
Although our suspicion is that many of the cell-cycle-related
proteins that are induced as a result of neuron disease or injury
are bystanders of p130 hyper-phosphorylation and play little if
any role in death, others may contribute. For instance, up-
regulation of cyclins B and E has been noted in AD
[71,109,110]. These in turn activate Cdk1 and Cdk2, respec-
tively both of which can target Rb family members [111,112].
Activation of these kinases may thus mimic or augment the
death-promoting actions of Cdk4 in neurons. In addition such
kinase may have other relevant targets. For instance, Cdk1 can
target and activate the pro-apoptotic BH3-domain molecule
BAD [2]. Another potential player is Cdk7 which phosphor-
ylates and activates other cdks including Cdks 1,2 and 4. Cdk7
levels are reported to be elevated in susceptible neurons in AD
[113].
The presence of markers for various stages of the cycle in
disease-affected neurons has led to suggestions that such cells
undergo an “aborted” or “dysregulated” cell cycle and that this
is what is responsible for their demise, perhaps by triggering
death-promoting check point controls. In our view, the critical
event is not the attempt to synthesize DNA or to traverse the
cycle, but rather the de-repression of genes such as B- and C-
Myb that can have multiple functions in addition to promoting
proliferation. For example, depending on the cellular context,
B-Myb can induce either proliferation or cell survival [49,50]
or, as reviewed here, neuron death [41,51]. As we argue below,
the choice between these actions and the reason that Myb is fatal
in a neuronal context, may depend on which additional
transcriptional regulators are present.
Another point to consider regarding the relationship
between cell cycle and neuron death in disease is that in
our model, the key E2F and Rb family proteins involved are
E2F4 and p130. Our culture experiments indicate that these
are the major family members complexed with DNA and the
Myb promoter in healthy post-mitotic neurons and that such
associations are lost upon activation of Cdk4 and result in
death. Present findings indicate that E2F4 and p130 are not
generally involved in regulating cell proliferation (in contrast
to E2F1–3 and pRb and p107) and that they appear at high
levels in the nervous system when neurons become post-
mitotic [114,115]. In neurological diseases, the consequence
of losing E2F4–p130 complexes due to activation of Cdk4
may therefore be to trigger death rather than replication (see
[47]).6. Neurological disorders and trophic factor deprivation
We have drawn parallels here between the apoptotic
pathways involved in neuron death associated with devel-
opment and with disease. Observations that treatments such
as exposure to β-amyloid can rapidly activate this mechan-
ism suggest that it can occur independently of loss of
trophic signaling. On the other hand, one consequence of a
number of neurodegenerative disorders and of nervous
system trauma is impairment or loss of access to and/or
retrograde transport of trophic factors [116,117]. Thus, the
mechanism described here by which cell cycle molecules
contribute to neuron death in neurological disorders may be
driven both by direct apoptotic stimuli as well as by loss of
trophic support.
7. The potential role of aggregated proteins and
proteasomal dysfunction in activation of the apoptotic
cell cycle pathway in neurodegenerative disorders
Dysfunction of the ubiquitin-proteasomal system is an
additional potential, and not necessarily mutually exclusive
contributor to activation of the neuronal apoptotic cell cycle
pathway. There is accumulation of aggregated proteins in a
number of degenerative disorders and this may cause or be
the result of reduced neuronal ubiquitin-proteasomal activity
(reviewed in [118,119]). It has been further suggested that
failure of the ubiquitin-proteasomal system triggers neuron
death and degeneration in such diseases [118,119]. The
ubiquitin-proteasomal system plays a major role in regulation
of cell cycle by degrading key proteins such as cyclins that
promote transition from one phase of the cycle to another
(reviewed in [120]). A relevant example is CycD which is
degraded by the proteasomal system to prevent activation of
cdks such as cdk4 and movement of cells into G1/S. Thus,
one could imagine that a neuron with compromised
proteasomal function might accumulate CycD as well as
other potential activators of the apoptotic cell cycle pathway.
Evidence to support this concept has come from experiments
with cultured cerebellar neurons induced to die by removal of
supporting levels of K+ or by treatment with proteasomal
inhibitors [65]. Several additional studies have shown that
neuron death induced by proteasomal inhibitors induce and
require activation of the cell cycle machinery, including Cdk4
[66,67]. Thus, irrespective of the initial cause, the reduction
of ubiquitin-proteasomal function that occurs in neurodegen-
erative disorders could contribute to activation of the apop-
totic pathway described here.
8. Cell cycle molecules are necessary, but not sufficient
triggers of neuron death
We have argued that activation of cell cycle molecules is
necessary for neuron death in development and disease.
However, they are unlikely to be sufficient in this regard. Even
in systems in which there is strong evidence for an essential
role of cell cycle molecules in neuron death, additional
398 L.A. Greene et al. / Biochimica et Biophysica Acta 1772 (2007) 392–401required pathways have been uncovered. A good example is
the pathway dependent on activation of the c-Jun N-terminal
protein kinases (JNKs). The JNK pathway has been implicated
as required for neuron death associated with diverse causes
including AD [121,122], PD [123], hypoxia/ischemia [124]
and trophic factor deprivation [125,126]. At least part of the
pro-apoptotic activity of JNKs appears to be due to their
capacity to phosphorylate and activate the transcription factor
c-Jun [126]. One aspect that the JNK pathway shares in
common with the apoptotic cell cycle pathway described here
is that it too can lead to activation of the pro-apoptotic protein
Bim in neurons. This has been observed thus far for NGF
deprivation [55,127], ischemia [128] and β-amyloid exposure
[S.C. Biswas and L.A. Greene, unpublished]. Moreover,
induction of Bim by apoptotic stimuli in neurons is suppressed
by inhibition of either the cell cycle or JNK pathways [35].
Thus, it appears that both pathways must be activated
simultaneously to promote maximum Bim induction and
death. Yet a third transcriptional pathway can also regulate
Bim expression in neurons, and that is one involving the
FOXO subfamily of Forkhead transcription factors [129].
FOXO appears to be involved in both Bim induction and in
death evoked by NGF deprivation [129]. In the presence of
NGF, FOXO proteins are phosphorylated by a PI3K/AKT-
dependent pathway and are excluded from the nucleus; with
NGF deprivation, de-phosphorylation permits FOXO move-
ment to the nucleus and regulation of death-promoting genes
including Bim [130].
If at least three independent transcriptional pathways
appear to regulate Bim expression in neurons and if each
plays a required role in death, how is this coordinated?
Examination of the Bim promoter reveals conserved binding
sites for Myb [35] and FOXO [129] proteins. In addition, we
find that the promoter also possesses a binding site for c-Jun
[S.C. Biswas and L.A. Greene, unpublished]. Thus, the Bim
promoter contains regulatory binding sites for products of all
three pathways (i.e. the cell cycle, JNK and FOXO
pathway). We have further observed that inhibition of any
one of the three pathways is sufficient to block NGF-
deprivation-induced activation of a reporter driven by the
Bim promoter [S.C. Biswas and L.A. Greene, unpublished].
These findings point to and support a model in which neuron
death requires the convergence of multiple independent
pathways to induce the pro-apoptotic protein Bim. That is,
under physiologic conditions, each of the pathways appears
to be required for Bim induction and for neuron death, but
none is sufficient. For full Bim induction and for neuron
death, all three pathways need to be activated simultaneously.
One possible reason for the evolution of such a mechanism
is that it acts as a “failsafe” to protect neurons from dying if
only a single pathway is activated inappropriately. This
consideration may also explain why Myb induction might
lead to death in a neuronal context, but not in proliferating
cells. That is, death would only occur if the complementary
transcription factors were activated and this would not be the
case for proliferating cells in which FOXO proteins are
inactivated by growth-factor-dependent PI3K/AKT signaling.This convergence model is also consistent with the
progressive loss of neurons that characterizes many neuro-
degenerative disorders. If neuron death in such diseases
requires a threshold level of activation of pro-apoptotic
proteins such as Bim, this would not occur until all three
pathways were sufficiently activated.
9. Therapeutic perspectives
The characterization of a pathway that is dependent on
defined cell cycle molecules such as Cdk4 and that is required
for neuron death in disease opens the door to specific
therapeutic intervention. One obvious approach that appears
promising thus far in models of spinal cord injury [100] and
ischemia/stroke [94] is the use of small molecule cdk inhibitors.
Issues such as specificity, side effects on proliferating tissues,
and access to the nervous system must be considered before
moving forward. Fortunately, mainly due to the potential use of
such agents for treatment of cancers, efforts are underway to
develop a variety of drugs that are selective for specific cdks
[33,131]. However, a major, though presumably soluble,
roadblock in evaluating such drugs for their neuroprotective
actions in suitable cell and animal models has been their limited
accessibility to the overall research community. Another issue is
whether such agents might be useful for inhibition of neuron
death in progressive neurodegenerative disorders. It remains to
be seen whether even the most specific cdk inhibitors could be
tolerated for prolonged periods of time and whether blockade of
neuron death in these disorders is sufficient to yield therapeutic
effects.
The model we have described here includes molecules in
addition to cdks. This raises the possibility that these too might
be considered as potential therapeutic targets. One advantage of
blocking the death pathway at such levels is that they are
upstream of activation of the core apoptotic machinery and thus
of cellular degeneration due to mitochondrial dysfunction. Bim
is attractive in this regard in that, based on the viability of Bim
null mice, it appears to be dispensable for survival of the
organism. Moreover, basal Bim levels in normal brain appear to
be very low. Various strategies such as targeted siRNAs or
antisense oligonucleotides or site-specific drugs that interact
with Bim and block its interaction with anti-apoptotic Bcl2
family members could thus prove useful in sustaining neuron
survival in disease.
It is not unlikely that the cell-cycle-related molecular
pathway recounted here is more complex than presently
understood and that it possesses additional components and
regulatory features. Although this would further challenge our
capacity to understand the mechanisms that govern neuron
death in development and disease, identifying additional
pathway components may also provide new opportunities and
targets for therapeutic intervention.
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